Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43921128" target="_blank" >RIV/00216208:11120/21:43921128 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/21:10423681 RIV/00216208:11130/21:10423681 RIV/68407700:21340/21:00356792 RIV/68407700:21460/21:00356792

Výsledek na webu

<a href="https://doi.org/10.1016/j.ijrobp.2021.02.014" target="_blank" >https://doi.org/10.1016/j.ijrobp.2021.02.014</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijrobp.2021.02.014" target="_blank" >10.1016/j.ijrobp.2021.02.014</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes

Popis výsledku v původním jazyce

PURPOSE: To analyse the 5-year biochemical disease free survival (bDFS) and late toxicity profile in patients with prostate cancer treated with pencil beam scanning (PBS) proton radiotherapy. MATERIAL AND METHODS: Between January 2013 and March 2016, 284 prostate cancer patients were treated utilising IMPT (Intensity Modulated Proton Therapy), with an ultra-hypofractionated schedule (36.25 GyE/5 fractions). Five patients were immediately lost from follow-up and thus were excluded from analysis. Data for 279 patients were prospectively collected and analysed with a median follow-up time of 56,5 (range 3.4 - 87.5) months. The mean age at time of treatment was 64.5 (40.1-85.7) years, median PSA value was 6.35 μg/l (0.67-17.3 μg/l). 121 (43.4%) patients had low risk, 125 pts (44.8%) had favorable and 33 (11.8%) unfavorable intermediate risk cancer. 49 (17.6%) patients underwent neoadjuvant hormonal therapy, no patients had adjuvant hormonal therapy. bDFS and late toxicity profiles were evaluated. RESULTS: The median treatment time was 9 days (range 7-18 days). The 5-year bDFS was 96.9%, 91.7 and 83.5% for the low-, favorable and unfavorable intermediate-risk group, respectively. Late toxicity (CTCAE-v.4) was: Gastrointestinal (GI): G1-62 patients (22%), G2-20 (7.2%), G3-1 (0.36%); Genitourinary (GU): G1-80 (28.7%), G2-14 (5%), no G3 toxicity was observed. PSA relapse was observed in 17 patients (6.1%), lymph node or bone recurrence was detected in 11 patients. Four (1.4%) local recurrences were detected. Nine (3.2%) died from causes unrelated to prostate cancer. No deaths related to prostate cancer were reported. CONCLUSION: Ultra-hypofractionated proton beam radiotherapy for prostate cancer is effective with long term bDFS comparable with other fractionation schedules and with minimal serious long-term GI and GU toxicity.

Název v anglickém jazyce

Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes

Popis výsledku anglicky

PURPOSE: To analyse the 5-year biochemical disease free survival (bDFS) and late toxicity profile in patients with prostate cancer treated with pencil beam scanning (PBS) proton radiotherapy. MATERIAL AND METHODS: Between January 2013 and March 2016, 284 prostate cancer patients were treated utilising IMPT (Intensity Modulated Proton Therapy), with an ultra-hypofractionated schedule (36.25 GyE/5 fractions). Five patients were immediately lost from follow-up and thus were excluded from analysis. Data for 279 patients were prospectively collected and analysed with a median follow-up time of 56,5 (range 3.4 - 87.5) months. The mean age at time of treatment was 64.5 (40.1-85.7) years, median PSA value was 6.35 μg/l (0.67-17.3 μg/l). 121 (43.4%) patients had low risk, 125 pts (44.8%) had favorable and 33 (11.8%) unfavorable intermediate risk cancer. 49 (17.6%) patients underwent neoadjuvant hormonal therapy, no patients had adjuvant hormonal therapy. bDFS and late toxicity profiles were evaluated. RESULTS: The median treatment time was 9 days (range 7-18 days). The 5-year bDFS was 96.9%, 91.7 and 83.5% for the low-, favorable and unfavorable intermediate-risk group, respectively. Late toxicity (CTCAE-v.4) was: Gastrointestinal (GI): G1-62 patients (22%), G2-20 (7.2%), G3-1 (0.36%); Genitourinary (GU): G1-80 (28.7%), G2-14 (5%), no G3 toxicity was observed. PSA relapse was observed in 17 patients (6.1%), lymph node or bone recurrence was detected in 11 patients. Four (1.4%) local recurrences were detected. Nine (3.2%) died from causes unrelated to prostate cancer. No deaths related to prostate cancer were reported. CONCLUSION: Ultra-hypofractionated proton beam radiotherapy for prostate cancer is effective with long term bDFS comparable with other fractionation schedules and with minimal serious long-term GI and GU toxicity.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

<a href="/cs/project/EF16_019%2F0000766" target="_blank" >EF16_019/0000766: Inženýrské aplikace fyziky mikrosvěta</a><br>

Návaznosti

O - Projekt operacniho programu

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Radiation: Oncology, Biolology, Physics

ISSN

0360-3016

e-ISSN

—

Svazek periodika

110

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

1090-1097

Kód UT WoS článku

000664730500023

EID výsledku v databázi Scopus

2-s2.0-85103083164